NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies via the development of next generation radiopharmaceuticals, has announced a number of key management changes.
The company has also established a UK subsidiary office and moved its centre of operations as it prepares to start clinical trials for its camelid antibody therapeutics and imaging agents in Q4 2020.
Paul Edwards MBE has been appointed as Chief Executive Officer and will be joined by Robin Pakenham as Director of Finance and Operations. In addition, Ian Miscampbell will join the Board as a non-Executive Director.
Dr Hong Hoi Ting, the cofounder of the company becomes the Executive Chair as well as the Chief Scientific Officer.
Paul Edwards commented: “I am delighted to join NanoMab at this exciting stage of the company’s development. The founding team’s world-class expertise in radiopharmaceuticals has enabled development of an innovative pipeline of precision theranostics, combining imaging agents with therapeutics."
"The first candidates have already completed FIH studies and are now ready to be taken into clinic in the UK and Germany. Strong existing academic links and collaborations, combined with the comprehensive network of experienced trial sites, have made this strategic move to Europe a logical choice.”
